Aberrantly Glycosylated IgA1 As a Factor in the Pathogenesis of IgA Nephropathy

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2011 Feb 15

PMID 21318178

Citations 11

Authors

Mototsugu Tanaka

George Seki

Tomonosuke Someya

Michio Nagata

Toshiro Fujita

Affiliations

Soon will be listed here.

Abstract

Predominant or codominant immunoglobulin (Ig) A deposition in the glomerular mesangium characterizes IgA nephropathy (IgAN). Accumulated glomerular IgA is limited to the IgA1 subclass and usually galactose-deficient. This underglycosylated IgA may play an important role in the pathogenesis of IgAN. Recently, antibodies against galactose-deficient IgA1 were found to be well associated with the development of IgAN. Several therapeutic strategies based on corticosteroids or other immunosuppressive agents have been shown to at least partially suppress the progression of IgAN. On the other hand, several case reports of kidney transplantation or acquired IgA deficiency uncovered a remarkable ability of human kidney to remove mesangial IgA deposition, resulting in the long-term stabilization of kidney function. Continuous exposure to circulating immune complexes containing aberrantly glycosylated IgA1 and sequential immune response seems to be essential in the disease progression of IgAN. Removal of mesangial IgA deposition may be a challenging, but fundamental approach in the treatment of IgAN.

Citing Articles

Clinical and pathological findings of IgA nephropathy following SARS-CoV-2 infection.

Li H, Li Z, Wu Z, Wang F, Xing Y, Liu Y Clin Exp Med. 2024; 24(1):43.

PMID: 38400937 PMC: 10894116. DOI: 10.1007/s10238-023-01271-2.

The pathogenesis of COVID-19-induced IgA nephropathy and IgA vasculitis: A systematic review.

Farooq H, Rehman M, Asmar A, Asif S, Mushtaq A, Qureshi M J Taibah Univ Med Sci. 2021; 17(1):1-13.

PMID: 34602936 PMC: 8479423. DOI: 10.1016/j.jtumed.2021.08.012.

Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy Controls.

Sanders J, Hastings M, Moldoveanu Z, Novak J, Julian B, Bursac Z Int J Nephrol. 2018; 2017:8210641.

PMID: 29333295 PMC: 5733148. DOI: 10.1155/2017/8210641.

Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA Nephropathy.

Wang L, Li X, Shen H, Mao N, Wang H, Cui L Sci Rep. 2016; 6:30964.

PMID: 27485391 PMC: 4971536. DOI: 10.1038/srep30964.

IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.

Lechner S, Abbad L, Boedec E, Papista C, Stang M, Moal C J Am Soc Nephrol. 2016; 27(9):2622-9.

PMID: 26850635 PMC: 5004657. DOI: 10.1681/ASN.2015080856.

References

. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978; 13(2):159-65. DOI: 10.1038/ki.1978.23. View

Silva F, Chander P, PIRANI C, Hardy M . Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation. 1982; 33(2):241-6. View

Grande J . Role of transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med. 1997; 214(1):27-40. DOI: 10.3181/00379727-214-44066. View

Taniguchi Y, Yorioka N, Oda H, Yamakido M . Platelet-derived growth factor, interleukin (IL)-1 beta, IL-6R and tumor necrosis factor-alpha in IgA nephropathy. An immunohistochemical study. Nephron. 1996; 74(4):652-60. DOI: 10.1159/000189470. View

Manno C, Torres D, Rossini M, Pesce F, Schena F . Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009; 24(12):3694-701. DOI: 10.1093/ndt/gfp356. View

Smith A, Molyneux K, Feehally J, Barratt J . Is sialylation of IgA the agent provocateur of IgA nephropathy?. Nephrol Dial Transplant. 2008; 23(7):2176-8. DOI: 10.1093/ndt/gfn203. View

Taniguchi Y, Yorioka N, Masaki T, Asakimori Y, Yamashita K, Yamakido M . Localization of transforming growth factors beta1 and beta2 and epidermal growth factor in IgA nephropathy. Scand J Urol Nephrol. 1999; 33(4):243-7. DOI: 10.1080/003655999750015853. View

HIKI Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H . Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 2001; 59(3):1077-85. DOI: 10.1046/j.1523-1755.2001.0590031077.x. View

Ruef C, Budde K, Lacy J, Northemann W, Baumann M, Sterzel R . Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int. 1990; 38(2):249-57. DOI: 10.1038/ki.1990.193. View

10.

Moura I, Arcos-Fajardo M, Sadaka C, Leroy V, Benhamou M, Novak J . Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol. 2004; 15(3):622-34. DOI: 10.1097/01.asn.0000115401.07980.0c. View

11.

Narita I, Gejyo F . Pathogenetic significance of aberrant glycosylation of IgA1 in IgA nephropathy. Clin Exp Nephrol. 2008; 12(5):332-338. DOI: 10.1007/s10157-008-0054-5. View

12.

Radford Jr M, Donadio Jr J, Bergstralh E, Grande J . Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997; 8(2):199-207. DOI: 10.1681/ASN.V82199. View

13.

Zhu L, Tang W, Li G, Lv J, Ding J, Yu L . Interaction between variants of two glycosyltransferase genes in IgA nephropathy. Kidney Int. 2009; 76(2):190-8. DOI: 10.1038/ki.2009.99. View

14.

Niemir Z, STEIN H, Noronha I, Kruger C, Andrassy K, Ritz E . PDGF and TGF-beta contribute to the natural course of human IgA glomerulonephritis. Kidney Int. 1995; 48(5):1530-41. DOI: 10.1038/ki.1995.443. View

15.

Levinsky R, BARRATT T . IgA immune complexes in Henoch-Schönlein purpura. Lancet. 1979; 2(8152):1100-3. DOI: 10.1016/s0140-6736(79)92505-4. View

16.

Seedat Y, Nathoo B, Parag K, Naiker I, Ramsaroop R . IgA nephropathy in blacks and Indians of Natal. Nephron. 1988; 50(2):137-41. DOI: 10.1159/000185144. View

17.

Novak J, Vu H, Novak L, Julian B, Mestecky J, Tomana M . Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int. 2002; 62(2):465-75. DOI: 10.1046/j.1523-1755.2002.00477.x. View

18.

Tang S, Tang A, Wong S, Leung J, Ho Y, Lai K . Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2009; 77(6):543-9. DOI: 10.1038/ki.2009.499. View

19.

Koselj M, Rott T, Kandus A, Vizjak A, Malovrh M . Donor-transmitted IgA nephropathy: long-term follow-up of kidney donors and recipients. Transplant Proc. 1998; 29(8):3406-7. DOI: 10.1016/s0041-1345(97)00957-3. View

20.

Pozzi C, Bolasco P, Fogazzi G, Andrulli S, Altieri P, Ponticelli C . Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999; 353(9156):883-7. DOI: 10.1016/s0140-6736(98)03563-6. View